I don't disagree with this but let's wait to see if QTR writes an article. If he does "not" then that will be very telling...We'll see..............Beegz
tony,,,Qcor was my first investment in the Bio-Tech industry so I don't have a great deal of knowledge with a lot of the language in the abstract. However, I would view this as positive news regarding ACTH in the treatment of NS and it's potential in the future. Mikey or Oneleft and others are way ahead of me in this area so I'll defer to them ole boys. It's good data though..Sorry not much help..............Beegz
Seems like I heard on the News yesterday that a judge ruled or was about to rule on a suit against Yahoo requiring them to turn over the ID's of certain posters who allegedly made false statements involving either another person or company. Did anyone else see this or have the facts. I'll try to find it...Thanks.....Beegz.
The melanocortin system is a neuroimmunoendocrine hormone system that constitutes the fulcrum in the homeostatic control of a diverse array of physiological functions, including melanogenesis, inflammation, immunomodulation, adrenocortical steroidogenesis, hemodynamics, natriuresis, energy homeostasis, sexual function, and exocrine secretion. The kidney is a quintessential effector organ of the melanocortin hormone system with melanocortin receptors abundantly expressed by multiple kidney parenchymal cells, including podocytes, mesangial cells, glomerular endothelial cells, and renal tubular cells. Converging evidence unequivocally demonstrates that the melanocortin-based therapy using the melanocortin peptide adrenocorticotropic hormone (ACTH) is prominently effective in inducing remission of steroid-resistant nephrotic syndrome caused by various glomerular diseases, including membranous nephropathy, minimal change disease and focal segmental glomerulosclerosis, suggesting a steroidogenic-independent mechanism. Mechanistically, ACTH and other synthetic melanocortin analogues possess potent proteinuria-reducing and renoprotective activities that could be attributable to direct protection of glomerular cells and systemic immunomodulation. Thus, leveraging melanocortin signaling pathways using ACTH or novel synthetic melanocortin analogues represents a promising and pragmatic therapeutic strategy for glomerular diseases. This review article introduces the biophysiology of the melanocortin hormone system with an emphasis on the kidney as a target organ, discusses the existing data on melanocortin therapy for glomerular diseases, and elucidates the potential mechanisms of action